Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Phase 2

• Conditions: Advanced Solid Tumor
• Interventions: Drug: Anlotinib; Drug: pd-1 antibody

• Registration Number: NCT03975036
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors

Detailed Description

To observe the beneficial population and adverse reactions of anlotinib hydrochloride combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the safe and effective drug treatment dose in the combined program, so that more patients with advanced tumor with poor prognosis can benefit from the combined program

Study Timeline

• Status Verified: 2019-01
• Study Start: 2019-04-08
• Study First Submitted: 2019-05-23
• Study First Submitted QC: 2019-06-02
• Last Update Submitted: 2019-06-02
• Study First Posted: 2019-06-05
• Last Update Posted: 2019-06-05
• Primary Completion: 2020-06-08
• Study Completion: 2021-07-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Signed the informed consent form prior to patient entry.
2. There is at least one measurable lesion in the pathologically diagnosed advanced solid tumor, including non-small cell lung cancer, liver cancer, gastric cancer, colorectal cancer, pancreatic cancer, soft tissue sarcoma, malignant melanoma, gallbladder cancer, esophageal cancer, ovarian cancer, endometrial cancer and breast cancer
3. ≥ 18 and ≤ 70 years of age.
4. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.
5. Life expectancy of more than 3 months.
6. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥ 100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST ≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN, Cr clearance ≥ 60 mL/min;Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).
7. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 6 months after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 6 months after last dose of study drug.

Exclusion Criteria

1. uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite optimal medical therapy), grade II The above myocardial ischemia or myocardial infarction, poor control of arrhythmia (including QTc interval male ≥ 450 ms, female ≥ 470 ms).
2. Patients previously treated with anticancer therapies also have a Toxicity Level> 1 in NCI CTCAE.
3. A variety of factors that affect oral absorption (such as inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).
4. Patients with gastrointestinal bleeding risk may not be included, including the following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of melena and vomiting within 3 months; (3) ) For fecal occult blood (+) must be gastroscopy, clear whether the existence of gastrointestinal organic diseases.
5. Coagulation dysfunction (INR> 1.5, PT> ULN + 4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment.
6. Long-term, unhealed wounds or fractures.
7. Active bleeding, within 30 days after major surgery.
8. Intracranial metastasis.
9. Pregnant or lactating women.
10. Cytotoxic drug treatment, radiotherapy within 3 weeks after treatment; had taken two or more targeted drugs, or into the group before the other three months have been taking other targeted drugs.
11. Other malignant tumors in the past 3 years.
12. The investigators believe there is any condition that may harm the subject or result in the subject's inability to meet or perform the research requirements.
13. Huge metastasis / recurrence (tumor diameter> 5 cm)。
14. Malignant pleural effusion or ascites, causing NCI CTCAE grading 2 or more people with dyspnea.
15. Any allergy to apatinib should be excluded.
16. Severe liver and kidney dysfunction (grade 4) patients should be excluded.
17. Persons with a history of substance abuse who can not be abdicated or have mental disorders.
18. According to the judgment of the researcher, there is a concomitant disease that seriously endangers the patient's safety or affects the patient in completing the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Anlotinib&pd-1 antibody	pd-1 antibody	Anlotinib 10mg/d,q.d.,p.o.\&pd-1 antibody 200mg/d.q.3w.d.l.v
Anlotinib&pd-1 antibody	Anlotinib	Anlotinib 10mg/d,q.d.,p.o.\&pd-1 antibody 200mg/d.q.3w.d.l.v

Primary Outcome Measures

Name	Time	Method
Progression-free Survival (PFS)	up to 2 year	From date of randomization until the date of first documented progression or date of death from any cause

Secondary Outcome Measures

Name	Time	Method
Overall survival(OS)	up to 2 year	From date of randomization until the date of death from any cause
Objective Response Rate (ORR)	up to 1 year	From date of randomization until the date of death from any cause
Disease Control Rate (DCR)	up to 1 year	Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.

Trial Locations

Locations (1)

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China